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Abstract
Background: Pneumococcal pneumonia causes significant morbidity and mortality among adults. Given limitations of
diagnostic tests for non-bacteremic pneumococcal pneumonia, most studies report the incidence of bacteremic or invasive
pneumococcal disease (IPD), and thus, grossly underestimate the pneumococcal pneumonia burden. We aimed to develop
a conceptual and quantitative strategy to estimate the non-bacteremic disease burden among adults with community-
acquired pneumonia (CAP) using systematic study methods and the availability of a urine antigen assay.
Methods and Findings: We performed a systematic literature review of studies providing information on the relative yield
of various diagnostic assays (BinaxNOWH S. pneumoniae urine antigen test (UAT) with blood and/or sputum culture) in
diagnosing pneumococcal pneumonia. We estimated the proportion of pneumococcal pneumonia that is bacteremic, the
proportion of CAP attributable to pneumococcus, and the additional contribution of the Binax UAT beyond conventional
diagnostic techniques, using random effects meta-analytic methods and bootstrapping. We included 35 studies in the
analysis, predominantly from developed countries. The estimated proportion of pneumococcal pneumonia that is
bacteremic was 24.8% (95% CI: 21.3%, 28.9%). The estimated proportion of CAP attributable to pneumococcus was 27.3%
(95% CI: 23.9%, 31.1%). The Binax UAT diagnosed an additional 11.4% (95% CI: 9.6, 13.6%) of CAP beyond conventional
techniques. We were limited by the fact that not all patients underwent all diagnostic tests and by the sensitivity and
specificity of the diagnostic tests themselves. We address these resulting biases and provide a range of plausible values in
order to estimate the burden of pneumococcal pneumonia among adults.
Conclusions: Estimating the adult burden of pneumococcal disease from bacteremic pneumococcal pneumonia data alone
significantly underestimates the true burden of disease in adults. For every case of bacteremic pneumococcal pneumonia,
we estimate that there are at least 3 additional cases of non-bacteremic pneumococcal pneumonia.
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Introduction
Community-acquired pneumonia (CAP) is a significant cause of
morbidity and mortality among adults worldwide, of which a
significant proportion is believed to be caused by Streptococcus
pneumoniae (pneumococcus). The World Health Organization
(WHO) estimated in 2005 that among all age groups, pneumo-
coccal disease caused an estimated annual 1.6 million deaths [1].
Although the global pneumococcal disease burden among children
is well understood, with an estimated 13.9 million cases of
pneumococcal pneumonia occurring among children ,5 years of
age in 2000 [2,3], the pneumococcal pneumonia burden among
adults is not well characterized, impeding policy formulation for
prevention and treatment.
In the pre-antibiotic era, when organisms were identified by
culture and mouse inoculation, 95% of lobar pneumonia cases [4]
were attributed to pneumococcus. S. pneumoniae is still thought to
be the most common etiologic agent of CAP [5,6,7,8] but is now
identified in a much lower proportion of patients than histor-
ically.This change is thought due to a decrease in microbiological
testing and the use of empiric antibiotics prior to testing, which has
increased the proportion of cases with unknown etiology [9].
Many of these cases are believed to be attributable to pneumo-
coccus [10].
Our objective was to develop a conceptual and quantitative
strategy to estimate the burden of non-bacteremic pneumococcal
pneumonia among adults by assessing the yield of blood cultures,
sputum cultures, and the Binax UAT to establish the proportion of
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pneumococcal pneumonia that is bacteremic and the proportion
of CAP attributable to pneumococcus (Figure 1) (See Appendix
S1: Said, MA, et al. Estimating the burden of pneumococcal
pneumonia among adults: the conceptual framework). Here, we
present estimates for these values, achieved through a systematic
review and meta-analysis of studies that report results of the Binax
UAT as well as blood culture and/or sputum culture. We also
present an estimate of the additional contribution of the Binax
UAT to the conventional diagnostic techniques of blood and
sputum culture.
Methods
Search Strategy
A conceptual framework and modeling strategy was first
developed (see Appendix S1). The model was used to guide this
systematic review and meta-analysis, which was prepared in
accordance with guidelines for meta-analyses of observational
studies [11] as well as the PRISMA statement [12]. A previously
existing review protocol for this particular study was not known to
exist. We performed three separate literature searches in Medline,
Embase, CINAHL, Global Health, and ISI Web of Knowledge
without date restrictions to identify papers reporting the diagnostic
yield of the BinaxNOWH S. pneumoniae urine antigen test (UAT) as
well as blood culture and/or sputum culture in cases of CAP
among adults and that would allow for a comparison between the
Binax UAT and at least one of the other two tests. The literature
search was performed by one author (MS) in May–June 2010 with
the assistance of a medical librarian. Titles and abstracts were
screened for potentially relevant citations and the full-text was
retrieved for studies reporting the diagnostic yield of the
BinaxNOWH S. pneumoniae urine antigen test (UAT) as well as
blood culture and/or sputum culture in cases of CAP among
adults. The first search aimed to identify papers that reported the
usefulness of the Binax UAT in diagnosing pneumococcal
pneumonia; in Pubmed, the following search terms were used:
(("binax"[all fields] OR "binaxnow" OR "urinary antigen test"))
AND ("Streptococcus pneumoniae"[Mesh] OR "Pneumococcal
Infections"[Mesh] OR "streptococcus pneumoniae"[all fields] OR
"pneumococcal"[all fields] OR "diplococcus pneumoniae"[all
fields] OR "pneumococcus"[all fields] OR "pneumococci"[all
fields] OR "S. pneumoniae"[all fields] OR "pneumococcal
infection"). The second search aimed to identify papers that
reported the usefulness of the Binax urinary antigen test in all cases
of pneumonia; search terms used were: (("Pneumonia"[Mesh] OR
"pneumonia")) AND ("binax" OR "binaxnow" OR "urine
antigen" OR "urinary antigen"). The third search broadened the
terms used to identify studies using the Binax UAT by including
the search terms "streptococcus pneumoniae antigen" OR
"urinary pneumococcal antigen". References lists of obtained
papers as well as suggestions from other authors were used to
identify additional studies.
A study was eligible for inclusion if it reported primary data
from human studies of radiologically confirmed adult pneumonia
cases. We considered all studies that reported results of the Binax
UAT as well as blood culture and/or sputum culture. We
excluded studies that looked at particular patient populations that
were not representative of the general adult CAP population; for
example, a study conducted among patients with malignancy. We
chose not to exclude a single paper in which all patients were
infected with HIV, as we were particularly interested in how HIV
infection might affect the outcome measures. Studies about cases
already identified as pneumococcal were excluded in order to
reduce bias. We included studies utilizing the Binax UAT on both
concentrated and non-concentrated urine. Sputum culture results
were accepted only if sputum quality criteria were used. All foreign
language articles were translated, either through electronic or
official translation services. Study population characteristics, case
ascertainment and diagnostic methods, and relevant outcome data
were abstracted from studies after full-text screening. We also
attempted to contact the authors of potentially relevant studies to
obtain additional information, including the number of patients
undergoing each diagnostic test, the number of positive test results,
and the overlap in positive results among the three methods for
detection (Figure 2).
Pneumococcal pneumonia was defined as radiographic pneu-
monia in addition to at least one positive laboratory test: a blood
culture or sputum culture positive for pneumococcus or a positive
Binax UAT. Bacteremic pneumococcal pneumonia was defined as
having a blood culture positive for pneumococcus, and non-
bacteremic was defined as having a sputum culture positive for
pneumococcus and/or a positive Binax UAT without a blood
culture positive for pneumococcus.
Study Selection
Of the 488 articles originally identified, 140 were chosen for full
text screening. Of these, 75 were identified to have potentially
useful information on comparative diagnostic yield of the tests;
authors were contacted to provide additional information and
clarification. When a subset of the study population contained a
population of CAP patients thought appropriate for inclusion, (i.e.
a study of patients with lower respiratory tract infections among
whom some were identified as having radiologically confirmed
CAP), the author was asked to submit data on the desired subset.
When an abstract without a published paper was identified that
was thought to represent a study that might include the needed
data, the author was also asked for additional data. Authors known
Figure 1. The relationships between CAP1, non-bacteremic
pneumococcal pneumonia, and bacteremic pneumococcal
pneumonia.
doi:10.1371/journal.pone.0060273.g001
1CAP = Community Acquired Pneumonia.
Adult Pneumococcal Pneumonia Burden
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to have worked or be working on a study that was thought to be
suitable but had not yet been published were also contacted.
Contact was conducted over email; if no email address for a
contacting author was identifiable, a letter was sent by mail.
Several publications reported results from the same cohort of CAP
patients and were classified as one study. Contact was made with a
representative from 49 of the 75 papers; a completed abstraction
form was returned for 33 study cohorts, not of all which were
found to meet criteria to be included in the study. Six of the studies
included in the final analysis were included based on only the
information provided in the published paper, as we were unable to
communicate with the author. Thirty-five studies were ultimately
included in the analysis.
Data extraction
Extracted data included the country in which the study was
conducted, the time period over which the study took place, the
language in which the paper was published, the nature of the study
population, the presence or absence of a chest x-ray requirement
in the diagnosis of pneumonia, the presence or absence of criteria
by which to judge sputum quality, the mean age of participants,
the percent of participants that were hospitalized, the percent of
patients in an ICU, the mean PSI score and the distribution of
participants among the five PSI classes, the percent of participants
vaccinated against pneumococcus, the percent of patients with
HIV, the percent of patients who came from a nursing home, the
percent of patients who received antibiotics before diagnostic
testing, the numbers of patients who underwent each diagnostic
test, whether concentrated or unconcentrated urine was used to
perform the Binax UAT, the numbers of study participants with
positive blood cultures, sputum cultures, and the Binax UAT and
the overlap in positivity of these test results, the numbers of
participants with positive test results for each of the diagnostic tests
studied stratified by whether they had received antibiotics prior to
diagnostic testing, and the number of positive test results for each
of the diagnostic tests studied stratified by the Pneumonia Severity
Index (PSI) class or CURB criteria. Data were extracted and
classified by one author (MS) and entered into a Microsoft Access
2007 database.
Statistical Analysis
Studies in which only two diagnostic tests were used were
weighted the same as those studies in which three diagnostic tests
were used, but these studies did not contribute to all proportions
calculated. In cases in which zero positive cases were identified, we
Figure 2. The relationship in diagnostic test yield of blood culture, sputum culture, and the Binax UAT2.
doi:10.1371/journal.pone.0060273.g002
2UAT = Urinary Antigen Test
Adult Pneumococcal Pneumonia Burden
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added 0.5 to the numerator and 1.0 to the denominator, as study
weights (the inverse of the variance) would otherwise be undefined.
Studies were stratified by the proportion of study participants
who received antecedent antibiotics into high and low categories.
This proportion was not known for three studies. In two studies
from Spain, the proportion was assumed to be the mean of the
proportion of other studies from Spain. In a study among Navajo,
the proportion was assumed to be low, and this study was
categorized with other studies in which the proportion on
antibiotics was low.
Severity of illness was defined using the Pneumonia Severity
Index (PSI), which uses an algorithm to identify patients with CAP
at low risk of dying within 30 days of presentation: a score of 1
represents the lowest risk and a score of 5 represents the highest
risk [13]. In some cases, studies that did not record the patients’
PSI class were characterized as having severe or non-severe
populations based on the proportion in the ICU or the proportion
hospitalized.
The methods and estimates were developed through an
interactive process that included discussions with an independent
Expert Review Panel as well as independent consultations with
additional experts on CAP and pneumococcal pneumonia.
Revisions were based on their comments and suggestions.
We sought to determine the proportion of pneumococcal
pneumonia that is bacteremic, the proportion of CAP attributable
to pneumococcus, and the contribution of the Binax UAT in
diagnosing pneumococcal pneumonia over and beyond conven-
tional culture techniques. Random effects meta-analysis to
summarize the results was used because significant heterogeneity
across studies was observed [14]. Analysis was done on the log-
transformed study estimates. The numbers of study participants
who underwent blood cultures, sputum cultures, or the Binax
UAT were known; however, the numbers of people who
underwent more than one diagnostic test were not (we knew that
x people underwent blood culture and y people underwent sputum
culture but not if the person who underwent blood culture was
part of the group who underwent sputum culture). Thus, to
calculate the proportion of CAP identified as pneumococcal, we
used the total study population as the denominator, assuming all
subjects were tested by all methods. We then evaluated the
proportion of CAP identified as pneumococcus by blood culture,
sputum culture, or the Binax UAT among those who actually
underwent each test.
Sensitivity analysis was done by excluding outlying study values
in order to determine their influence. We also stratified studies by
proportion of pneumococcal pneumonia cases who were HIV-
infected (,20% or unknown vs. $20%), severity of illness, and
prior antibiotic use. Univariate linear regression (which assigns
equal weights to studies) and random effects meta-regression were
used to explore potential confounding factors for the proportion of
CAP identified as pneumococcus. The Monte Carlo permutation
test was applied to the meta-regression to obtain p-values adjusted
for multiple testing [15]. A significance level of 0.05 was used to
identify potential confounders between studies, which included
hospital admission, HIV infection, antibiotics received before
diagnostic testing, mean age, mean Pneumonia Severity Index
(PSI), and whether concentrated urine was used for the Binax
UAT testing. Finally, we analyzed the effect of (a) receipt of
antibiotics before specimen collection and (b) PSI class comparing
higher (IV–V) vs. lower (I–III) PSI classes on diagnostic yield.
Heterogeneity of studies was evaluated by the I-squared test.
Statistical analyses were done in Stata (version 11) [16].
Results
Review of citations’ titles and abstracts identified from a
systematic literature search and hand searching of citation lists
from other relevant published studies yielded 488 articles
(Figure 3). Thirty-five studies reported the yield of the Binax
UAT relative to blood culture and/or sputum culture in
diagnosing adult pneumococcal pneumonia and were included
in the analysis; of these, 28 had data for the relationship of positive
results for all three diagnostic tests and were used in the
calculations of the proportion of pneumococcal pneumonia that
is bacteremic and the proportion of CAP attributable to
pneumococcus. The included studies represented data from 18
countries (Table 1), predominantly from Europe and North
America. The majority of included studies were prospective studies
of CAP etiology among hospitalized cases.
The proportion of pneumococcal pneumonia that was bacter-
emic ranged from 2.2% to 50.9% (median 28.9%, IQR 14.8% to
33.4%). In the meta-analysis, the proportion of pneumococcal
pneumonia estimated to be bacteremic was 24.8% (95% CI:
21.3%, 28.9%) (Figure 4). The proportion of CAP identified as
pneumococcus varied by diagnostic test. It was smallest with blood
cultures and greatest with the Binax UAT (Figure 5). The meta-
estimate of the proportion of CAP attributable to pneumococcus
was 27.3% (95% CI: 23.9%, 31.1%). Inclusion criteria were used
to maximize the quality of the studies included in the analysis.
However, studies with larger population sizes were thought to
provide more reliable proportions and were analyzed separately in
order to assess this particular bias. When studies with ,200
participants were compared with studies with $200 participants,
the proportion of CAP attributable to pneumococcus was 27.4%
(95% CI: 22.2%, 33.9%) in the smaller studies compared to 26.7%
(95% CI: 22.7%, 31.4%) in the larger studies.
When we used as the denominator the number of people who
actually underwent a diagnostic test rather than the total study
sample size to evaluate the pneumococcal yield of each individual
test, the proportion of CAP diagnosed as pneumococcal rose from
7.5% (95% CI: 6.4%, 8.8%) to 8.1% (95% CI: 7.0%, 9.5%) by
blood culture, from 9.8% (95% CI: 8.1%, 12.0%) to 19.9% (95%
CI: 16.9%, 23.4%) by sputum culture, and from 20.0% (95% CI:
17.4%, 23.1%) to 23.9% (95% CI: 21.7%, 26.4%) by the Binax
UAT.
The Binax UAT increased the diagnostic yield over and above
blood and sputum culture by an additional 11.4% (95% CI: 9.6%,
13.6%). Expressed as a ratio, the Binax UAT identified an
additional 0.87 cases (95% CI: 0.51, 1.36) for every case identified
as pneumococcal by blood and sputum culture.
We also stratified the results by prior antibiotic use, disease
severity, and HIV prevalence (Table 2). In meta-regression, none
of the included potential confounders were found to be
significantly associated with proportion estimates. There was a
high degree of heterogeneity in all outcomes of interest (e.g. I-
squared for the proportion of CAP identified as pneumococcal by
all three diagnostic tests was 91.6%), and none of the potential
confounders included in the meta-regression explained this
heterogeneity (adjusted p-values .0.05 for all covariates).
We further investigated the effects of prior antibiotic use and
PSI class (IV–V vs. I–III) on the diagnostic yield of each test and
calculated the risk ratio for having a positive blood culture, sputum
culture, or Binax UAT (Table 3). Prior antibiotics reduced the
relative diagnostic yield for blood cultures by 67% (95% CI: 53%,
77%), for sputum cultures by 34% (95% CI: 8%, 53%) and for the
Binax UAT by 26% (95% CI: 0%, 44%). The relative
pneumococcal diagnostic yield among those people with more
Adult Pneumococcal Pneumonia Burden
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severe disease (PSI class IV–V) compared to those with less severe
disease (PSI class I–III) increased for blood cultures by 72% (95%
CI: 38%, 115%), and for the Binax UAT by 31% (95% CI: 15%,
50%).
Discussion
Through evaluation of the relationship in diagnostic yield of
blood culture, sputum culture, and the Binax UAT in diagnosing
adult pneumococcal pneumonia, we estimated the proportion of
pneumococcal pneumonia that is bacteremic to be approximately
25% and, thus, the ratio of non-bacteremic pneumococcal
pneumonia to bacteremic pneumococcal pneumonia to be
approximately 3:1. Because this estimate assumed a normal
distribution, we also performed a bootstrap analysis [17] to
determine the ratio of non-bacteremic pneumococcal pneumonia
to bacteremic pneumococcal pneumonia, which gave a similar
result. The wide range among studies in the proportion of
pneumococcal pneumonia that was bacteremic could not be
explained by study size, study location, proportion of participants
undergoing sputum cultures and Binax UAT testing, proportion of
participants on antecedent antibiotics, and severity of illness;
however, in the two studies with the lowest proportion of
bacteremic cases, many people did not undergo blood cultures
and thus, some bacteremic cases were probably not identified. In
the study with the most extreme value for this proportion (2.2%),
only 11 of 80 study participants underwent blood culture testing,
likely leading to a proportion underestimate.
Figure 3. Flow diagram for the selection of studies.
doi:10.1371/journal.pone.0060273.g003
Adult Pneumococcal Pneumonia Burden
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This finding of a ratio of non-bacteremic to bacteremic
pneumococcal pneumonia of 3:1 is consistent with estimates from
the pre-antibiotic era, which suggested that for every case of
bacteremic pneumococcal pneumonia, there were 2–4 cases of
non-bacteremic pneumococcal pneumonia [18,19,20]. Diagnosis
at that time relied on extensive microbiological techniques and was
unaffected by antibiotic use. Although our estimates are similar to
those from the pre-antibiotic era, we used results from only three
diagnostic tests, and the test with the highest yield, the Binax
UAT, is known in cases of non-bacteremic pneumococcal
pneumonia to have a sensitivity of as low as 52% among patients
with sputum cultures positive for pneumococcus [21]. Further-
more, many patients in these etiologic studies received antecedent
antibiotics, and not all patients underwent every diagnostic test.
Thus, we believe that our estimate of the proportion of
pneumococcal pneumonia that is bacteremic represents a lower
limit of the true proportion.
We found that at least one-quarter of CAP cases are likely
attributable to pneumococcus. This is consistent with a systematic
review of 127 study cohorts among adults from 1966–1995 that
found that pneumococcus accounted for 24% of all pneumonia
cases [22]. Another source of validation is a study analyzing the
impact of infant pneumococcal conjugate vaccination on U.S.
pneumonia and influenza hospitalization and mortality rates for all
ages. The study estimated, using modeling techniques, a reduction
in the proportion of CAP attributable to pneumococcus from
about 35–40% in the pre-vaccine era to about 18–28% in the post-
vaccine era [23]. As the Binax UAT test was introduced around
the same time as the pediatric pneumococcal conjugate vaccine, it
is possible that the results from our analysis may reflect some
indirect effects of the vaccine. Our estimate of the proportion of
CAP attributable to pneumococcus is somewhat lower than the
estimate for children; using a vaccine-probe approach, a meta-
analysis of 4 randomized pediatric pneumococcal conjugate
vaccine efficacy trials estimated the proportion of radiologically
confirmed pneumonia attributable to pneumococcus to be 36%
[2]. However, some of the pediatric vaccine trials were conducted
in resource-limited countries and may explain the higher
pneumococcal pneumonia burden compared to our findings
among adults in high-resource settings.
All of the studies used to estimate the proportion of
pneumococcal pneumonia that is bacteremic and the proportion
of CAP attributable to pneumococcus by all 3 diagnostic methods
were performed in resource-rich countries; the study from
Nicaragua did not include data on the yield of blood cultures
and, thus, did not contribute to these estimates. Given true
differences in pneumonia epidemiology in resource-limited com-
pared to resource-rich populations, such as age distribution,
Figure 4. Forest plot for the proportion of pneumococcal pneumonia identified as bacteremic, sorted by proportion of study
participants who received antecedent antibiotics.
doi:10.1371/journal.pone.0060273.g004
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prevalence of nasopharyngeal pneumococcal colonization, the
prevalence of underlying illness (e.g. HIV), and the ability to
identify the etiology of CAP due to disparities in laboratory testing,
access to care, and antecedent antibiotic use, it is possible that both
the true and estimated proportion of pneumococcal pneumonia
that is bacteremic and the proportion of CAP attributable to
pneumococcus might differ. The paucity of data from resource-
limited settings, particularly Africa, makes these differences
difficult to assess. One recent study from Kenya, which used a
serotype-specific latex agglutination urine antigen test, estimated
by latent class analysis the proportion of CAP attributable to
pneumococcus in adults to be 46% (95% CI: 36%–57%), over
18% higher than what we found [24].
Etiology studies among adults in resource-limited settings often
use blood culture and sputum examination. By estimating the
additional contribution of the Binax UAT in diagnosing pneu-
mococcal pneumonia, we demonstrate that the Binax UAT may
identify an additional 11% with an etiology of pneumococcal
pneumonia compared to studies that only use blood culture and
sputum examination. A recent study in South Africa of a rapid
molecular assay for nasopharyngeal pneumococcal density in a
population with high HIV prevalence found, similar to this study,
Figure 5. The proportion of community-acquired pneumonia attributable to pneumococcus, according to diagnostic test results,
by individual studies3.
doi:10.1371/journal.pone.0060273.g005
Table 2. Meta-analysis of the proportion of pneumococcal pneumonia that is bacteremic and the proportion of CAP attributable
to pneumococcus, stratified by severity of disease, prior antibiotic use, and HIV status.
Prior antibiotic use Disease severity HIV Prevalence
Outcome Measure High (n =14) Low (n=14) High (n=12) Low (n=7) High (n =3) Low (n=21)
Proportion (%) of pneumococcal pneumonia that is
bacteremic (95% CI)
20.1 (15.2–26.6) 28.4 (23.6–34.1) 31.3 (26.1–37.5) 20.6 (13.1–32.5) 30.9 (28.1–33.9) 26.2 (22.0–31.2)
Proportion (%) of CAP attributable to pneumococcus
(95%CI)
26.4 (20.8–33.5) 28.0 (24.1–32.5) 27.3 (23.0–32.6) 25.8 (22.6–29.6) 37.3 (26.4–52.6) 25.9 (22.1–30.4)
doi:10.1371/journal.pone.0060273.t002
3Missing bars occur in studies in which there were insufficient data to populate
the entire Venn diagram and, thus, in which not all relationships could be
established.
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that blood culture, good quality sputum culture and gram stain
identified 15.4% of the population with pneumococcus and that
the Binax UAT added an additional 11.7% [25].
The majority of studies included only hospitalized patients; only
5 studies included non-hospitalized patients. When we excluded
these studies from the analysis, the results did not change
meaningfully. The proportion of pneumococcal pneumonia that
was bacteremic demonstrated an increasing trend in studies with
more severe disease, which is consistent with findings that
bacteremia is more common among patients with severe disease
[26]. The proportion of pneumococcal pneumonia that was
bacteremic was lower, although not statistically significantly lower,
in studies in which a high proportion of the study population
received antecedent antibiotics, likely indicating the greater effect
antibiotic use has on blood culture yield compared to other
diagnostic tests. The majority of studies included no patients with
known HIV infection. Among three studies with an HIV
prevalence $20%, a greater proportion of CAP was attributable
to pneumococcus than among the other studies. This finding is
consistent with studies that reported greater risk of developing IPD
or bacterial pneumonia among HIV-infected individuals com-
pared to the general population [27,28].
We were able to further investigate, through a meta-analysis of
risk ratios, the effect of antibiotic use and severity of illness on
pneumococcal diagnostic test positivity. As expected, we found a
decreased yield of blood culture and sputum culture among those
who had received previous antibiotics. We also found a decreased
yield of the Binax UAT after antibiotics, although the result was
not statistically significant. Previous studies have shown conflicting
results as to whether antecedent antibiotic use decreases Binax
UAT yield [29,30,31]. We found increased yield of the three
diagnostic tests with increased severity of disease, although for
sputum culture this was not statistically significant. Many studies
have shown that conventional diagnostic tests of blood culture and
sputum culture have higher yield among sicker patients [26,32,33].
Studies among adults have demonstrated the Binax UAT to have
a sensitivity of 77%–92% [21,29,34,35,36] in diagnosing bacter-
emic pneumococcal pneumonia and 52%–78% in diagnosing non-
bacteremic pneumococcal pneumonia [21,29,34,35], suggesting
that the UAT is more sensitive in bacteremic patients; however the
studies are difficult to compare as each defines non-bacteremic
pneumococcal pneumonia differently. In some, but not all studies,
the Binax UAT yield increased with higher PSI score [29,30,32].
There are a number of limitations to our study. Most notably,
our findings are best generalizable to CAP patients presenting to
hospital in developed countries. We only included studies in which
the Binax UAT was used and thus were not able to include many
studies from resource-limited countries. The direction of this bias
depends on multiple factors and is difficult to predict. Higher HIV
prevalence in some settings might lead to a higher true proportion
of CAP attributable to pneumococcus, but a lack of adequate lab
facilities in resource-limited settings might reduce the diagnostic
yield and thus suggest a lower reported proportion of CAP
attributable to pneumococcus. The studies included may also not
be representative of the general CAP population, as almost all the
patients were hospitalized and thus had moderate to severe disease
and/or likely increased prevalence of comorbidities. An outpatient
population with less severe disease would be expected to have a
smaller proportion of pneumococcal pneumonia that was bacter-
emic than a hospitalized patient population, and thus, our estimate
might underestimate the true proportion. By estimating the
additional contribution of the Binax UAT over the conventional
diagnostic tests (blood and sputum culture) and by estimating the
degree to which antecedent antibiotic use and severity of illness is
associated with diagnostic test yield, we aimed to provide a range
of plausible estimates. For example, although the estimates here
are representative of a hospitalized population in a resource-rich
setting, the finding that the Binax UAT identified an additional
0.87 cases (95% CI: 0.51, 1.36) for every case identified as
pneumococcal by blood or sputum culture could be used when
estimating the burden of pneumococcal pneumonia in populations
in which the Binax UAT was not used.
We were also limited by the fact that not all patients underwent
all diagnostic tests. Blood cultures were performed on 14%–100%
(median 97% and mean 89%) of participants. Sputum cultures
were performed on 20%–100% of participants (median 60% and
mean 60%); and the Binax UAT was performed on 6%–100%
(median 96% and mean 90%) of participants. By assuming that all
participants underwent each test, we underestimated the propor-
tion of people infected with pneumococcus. Because sputum
cultures were performed on fewer people than blood cultures,
when we calculated the proportion of CAP cases diagnosed as
pneumococcal by each diagnostic test using the true number of
study participants who underwent each test, rather than all study
participants, the yield of sputum culture rose significantly; thus,
this limitation may have led to an overestimation of the proportion
of pneumococcal pneumonia that is bacteremic. Furthermore, we
do not know whether those people who underwent certain
diagnostic tests were qualitatively different than those who did
not undergo certain diagnostic tests. If blood cultures were
collected more often by some clinicians than others, but urine was
collected on all subjects, this might bias our results to underes-
timate the proportion of pneumococcal pneumonia that is
bacteremic.
Finally, our results are constrained by the limitations in
sensitivity and specificity of the diagnostic tests themselves. For
Table 3. Meta-analysis of the association of prior antibiotic use and PSI class on the yield of blood culture, sputum culture, and the
Binax UAT.
Prior antibiotic use Pneumonia Severity Index Class
Diagnostic Test
Number of
studies Risk ratio1 (95% CI) P-value
Number of
studies Risk ratio2 (95% CI) P-value
Blood culture 17 0.33 (0.23–0.47) ,0.001 17 1.72 (1.38–2.15) ,0.001
Sputum culture 17 0.66 (0.47–0.92) 0.015 14 1.24 (0.98–1.56) 0.07
Binax UAT 17 0.74 (0.56–1.00) 0.047 16 1.31 (1.15–1.50) ,0.001
1Of positive yield; reference is no prior antibiotic use.
2Of positive yield; reference is Pneumonia Severity Index class I–III.
doi:10.1371/journal.pone.0060273.t003
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example, assuming that the Binax UAT is more sensitive among
bacteremic patients, it might miss a larger number of non-
bacteremic patients and lead to a falsely high proportion of
pneumococcal pneumonia thought to be bacteremic.
Our study shows that estimates of the number of pneumococcal
pneumonia adult cases that rely primarily on blood culture results
vastly underestimate the true burden of disease. The objective of
this analysis was not to conduct a meta-analysis of the tests’
performances but to provide a range of plausible values in order to
estimate, with tests known to be imperfect, the burden of non-
bacteremic pneumococcal pneumonia among adults. Additional
studies utilizing the Binax UAT and development and use of more
reliable tests for non-bacteremic pneumococcal pneumonia,
including possibly quantitative sputum or nasopharyngeal PCR,
will improve our understanding. The observed reduction in both
IPD and pneumococcal pneumonia among unvaccinated older
children and adults due to the indirect effects of pediatric
conjugate vaccine can also provide a measure of pneumococcal
pneumonia burden [23,37,38]. Through this and additional
studies, a better understanding of the adult disease burden can
help guide treatment and prevention strategies.
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